Valeant Pharmaceuticals Intl Inc (NYSE: VRX) Valeant Pharmaceuticals has had a rough time in the market, there’s no denying that. However, at the moment, I believe it’s time to buy. Today, we’ll talk about why the company has been struggling, what’s changed since, and why it’s time to buy VRX. So, let’s get right to … Read more
Valeant Pharmaceuticals (NYSE:VRX) On Monday March 21, 2016 shares of Valeant were halted pre-market before a major company announcement. The news that eventually came out was that the CEO of the company, Michael J. Pearson, would be resigning from the company. This is definitely bad news as it is never a good thing when a … Read more
Valeant Pharmaceuticals (NYSE:VRX) On Monday March 4, 2016 Valeant Pharmaceuticals fell down 7% in the morning as the company announced that it will have to delay its financial results. This left investors jittery and in panic mode, because they had and still have no clue why earnings are being pushed back so much. One possible … Read more
Rxi Pharmaceuticals (NASDAQ:RXII) On August 31, 2015 Rxi announced that the 30-day review period for its IND of RXI-109 for scarring of macular degeneration has passed its review period and the IND is now active. The whole point of the 30-day review period is for the FDA to look at pre-clinical data and conclude whether … Read more
Valeant Pharmaceuticals (VRX) & Salix Pharmaceuticals (SLXP) Valeant Pharmaceuticals had agreed to buy Salix Pharmaceuticals for about $10.4 billion dollars in an all cash type deal. Valeant currently has many approved drugs in various areas such as: skin, eyes, and oral type drugs. This addition of Salix Pharmaceuticals will give Valeant access to a gastrointestinal … Read more